Home

DP VII ASSOCIATES LP

CIK 1372932 · last filed 2016-11-03

DP VII ASSOCIATES LP is a corporate insider who has filed 25 SEC Form 4 insider transactions across 8 companies since 2008. Across all open-market trades the lifetime net is −$85.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $95.8K across reported positions. The firm reports its address in Princeton, NJ. 35 SEC filings were submitted jointly with JAMES C BLAIR.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$95.8K

Companies

8

Total Filings

25

Lifetime Open-Market Net

-$85.4K

Filer Profile

Reported Address
ONE PALMER SQ
STE 515
PRINCETON, NJ 08542
Related Filers
JAMES C BLAIR — 35 joint filings, latest 2016-11-03
BRIAN H DOVEY — 35 joint filings, latest 2016-11-03
Brian K Halak — 35 joint filings, latest 2016-11-03
JESSE I TREU — 35 joint filings, latest 2016-11-03
NICOLE VITULLO — 35 joint filings, latest 2016-11-03
KATHLEEN K SCHOEMAKER — 27 joint filings, latest 2015-08-20
DOMAIN PARTNERS IV LP — same reported address
DP IV ASSOCIATES LP — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Evoke Pharma Inc (OMED) Delisted 10%+ Owner 10,328 — — -$165.8K 2 2016-05-27
Achaogen, Inc. (AKAO) Delisted 10%+ Owner 33,890 — — $0 1 2014-03-17
TNDM 10%+ Owner 5,439 $17.62 $95.8K $0 1 2013-11-19
Esperion Therapeutics, Inc. (ESPR) Delisted 10%+ Owner 35,253 $3.18 $112.1K $67.1K 1 2013-07-02
Clovis Oncology, Inc. (CLVS) Delisted 10%+ Owner 48,464 $0.08 $3.9K -$520.0K 2 2013-03-06
CADENCE PHARMACEUTICALS INC (CADX) Delisted 10%+ Owner 43,354 — — -$29.9K 2 2013-02-05
Orexigen Therapeutics, Inc. (OREX) Delisted 10%+ Owner 5,064 — — $288.1K 12 2011-12-22
ZOGENIX, INC. (ZGNX) Delisted 10%+ Owner 21,156 $26.68 $564.4K $275.0K 2 2011-09-20

Recent Filings

25 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2016-11-03 — U −285,678 -$8.10M
2016-05-27 Evoke Pharma Inc (OMED) Delisted Sell (S) −35,280 -$165.8K EDGAR
2014-03-21 — Disp (D) −50,743 -$710.4K
2014-03-17 Achaogen, Inc. (AKAO) Delisted Conv (C) +33,890 $0 EDGAR
2013-11-19 TNDM Mixed +54,390 $0 EDGAR
2013-09-30 Evoke Pharma Inc (OMED) Delisted Conv (C) +19,006 $0 EDGAR
2013-07-02 Esperion Therapeutics, Inc. (ESPR) Delisted Mixed +35,253 $67.1K EDGAR
2013-03-06 Clovis Oncology, Inc. (CLVS) Delisted Sell (S) −29,400 -$723.1K EDGAR
2013-02-05 CADENCE PHARMACEUTICALS INC (CADX) Delisted Sell (S) −1,148 -$5.6K EDGAR
2013-01-24 CADENCE PHARMACEUTICALS INC (CADX) Delisted Sell (S) −4,788 -$24.3K EDGAR
Showing 1–10 of 25
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.